Key references: Choice of drug therapy for osteoporosis

Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 2016;27(5):1923–5. https://www.ncbi.nlm.nih.gov/pubmed/26510845
Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017;12(1):43. https://www.ncbi.nlm.nih.gov/pubmed/28425085
Eastell R, Rosen CJ, Black DM, Cheung L, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline. J Clin Endocrinol Metab 2019;104:[epub 25 March 2019 ahead of print]. https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/osteoporosis-in-postmenopausal-women
Ebeling P, Center J, Clifton-Bligh R, Cooper M, Ewald D, Singh M, et al. Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age. 2nd ed. Melbourne: The Royal Australian College of General Practitioners; 2017. https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/osteoporosis
Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 2017;102(2):354–8. https://www.ncbi.nlm.nih.gov/pubmed/27732330
Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int 2016;27(5):1917–21. https://www.ncbi.nlm.nih.gov/pubmed/26694598